

Carbamazepine

General:

Carbamazepine is a dibenzazepine derivative and belongs to the group of anticonvulsants. Its effect is based on blocking the post-tetanic potentiation by reducing polysynaptic responses. Predominant application areas are common focal, psychomotoric and grand mal attacks as well as trigeminal neuralgia. Side effects are drowsiness, giddiness, nausea, headache, ataxia, tremor, confusion, allergic reactions, liver damages and leukocytopenia. Carbamazepine shows structural and pharmacological similarity to tricyclic anti-depressants (e.g. imipramine). It is bound to plasma proteins to 65-80 %, the half-life amounts to 20-60 h.

Indication: Therapy monitoring

Material: 1 ml serum

Stability: 7 days (capped) at 2 to 8°C

Preanalytics: blood collection directly before the next intake

TAT: same day, FML

Method: MAIA

Units: mg/l

Ref.- range: Therapeutic: 4.0 - 12

For complete list of laboratory test offered at Freiburg Medical Laboratory, please visit <http://www.fml-dubai.com/parameter-listings/>